Literature DB >> 8694296

Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass.

M Kikura1, M K Lee, J H Levy.   

Abstract

There are no clinically available alternatives for reversing heparin in protamine-allergic patients. This study examined the ability of methylene blue, hexadimethrine, and vancomycin to reverse circulating heparin so that these compounds can be carefully examined in future placebo-controlled studies in humans. Heparin activity in blood obtained from extracorporeal circuits was reversed by adding protamine (13.5, 27.0, 81.1, 135.1, and 270.3 micrograms/mL), methylene blue (13.5, 27.0, 135.1, 202.7, 270.3, 337.8, 405.4, 473.0, 540.5, and 810.8 micrograms/mL), hexadimethrine (6.8, 13.5, 20.3, 27.0, 81.1, and 135.1 micrograms/mL), or vancomycin (13.5, 27.0, 135.1, 270.3, 540.5, and 810.8 micrograms/mL), and activated clotting times (ACTs) were measured with kaolin (n = 18). Heparinase-ACT was obtained to determine complete reversal. Heparin concentrations were 3.3 +/- 0.3 U/mL with ACT values of 485 +/- 97 s. The ACT at a protamine concentration of 81.1 micrograms/mL and at hexadimethrine concentrations of 81.1 and 135.1 micrograms/mL was not statistically different from heparinase-ACT; however, methylene blue or vancomycin did not reverse the anticoagulation at any concentrations. Hexadimethrine can reverse heparin-induced anticoagulation after cardiopulmonary bypass as well as protamine, although methylene blue or vancomycin did not neutralize heparin in vitro.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8694296     DOI: 10.1097/00000539-199608000-00004

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  9 in total

Review 1.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.

Authors:  Jennifer A Frontera; John J Lewin; Alejandro A Rabinstein; Imo P Aisiku; Anne W Alexandrov; Aaron M Cook; Gregory J del Zoppo; Monisha A Kumar; Ellinor I B Peerschke; Michael F Stiefel; Jeanne S Teitelbaum; Katja E Wartenberg; Cindy L Zerfoss
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

3.  Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins.

Authors:  Aleksandra Jakimczuk; Bartlomiej Kalaska; Kamil Kamiński; Joanna Miklosz; Shin-Ichi Yusa; Dariusz Pawlak; Krzysztof Szczubiałka; Andrzej Mogielnicki
Journal:  J Clin Med       Date:  2022-04-16       Impact factor: 4.964

4.  STS/SCA/AmSECT Clinical Practice Guidelines: Anticoagulation during Cardiopulmonary Bypass.

Authors:  Linda Shore-Lesserson; Robert A Baker; Victor Ferraris; Philip E Greilich; David Fitzgerald; Philip Roman; John Hammon
Journal:  J Extra Corpor Technol       Date:  2018-03

5.  A Nanoscale Tool for Photoacoustic-Based Measurements of Clotting Time and Therapeutic Drug Monitoring of Heparin.

Authors:  Junxin Wang; Fang Chen; Santiago J Arconada-Alvarez; James Hartanto; Li-Peng Yap; Ryan Park; Fang Wang; Ivetta Vorobyova; Grant Dagliyan; Peter S Conti; Jesse V Jokerst
Journal:  Nano Lett       Date:  2016-09-28       Impact factor: 11.189

6.  Inactivation of heparin by cationically modified chitosan.

Authors:  Barbara Lorkowska-Zawicka; Kamil Kamiński; Justyna Ciejka; Krzysztof Szczubiałka; Magdalena Białas; Krzysztof Okoń; Dariusz Adamek; Maria Nowakowska; Jacek Jawień; Rafał Olszanecki; Ryszard Korbut
Journal:  Mar Drugs       Date:  2014-06-30       Impact factor: 5.118

7.  Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin.

Authors:  Bartlomiej Kalaska; Kamil Kaminski; Emilia Sokolowska; Dominik Czaplicki; Monika Kujdowicz; Krystyna Stalinska; Joanna Bereta; Krzysztof Szczubialka; Dariusz Pawlak; Maria Nowakowska; Andrzej Mogielnicki
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

8.  The Toxicokinetic Profile of Dex40-GTMAC3-a Novel Polysaccharide Candidate for Reversal of Unfractionated Heparin.

Authors:  Emilia Sokolowska; Bartlomiej Kalaska; Kamil Kaminski; Alicja Lewandowska; Agnieszka Blazejczyk; Joanna Wietrzyk; Irena Kasacka; Krzysztof Szczubialka; Dariusz Pawlak; Maria Nowakowska; Andrzej Mogielnicki
Journal:  Front Pharmacol       Date:  2016-03-17       Impact factor: 5.810

9.  Serum Albumin-Peptide Conjugates for Simultaneous Heparin Binding and Detection.

Authors:  Qing Liu; Salla Välimäki; Ahmed Shaukat; Boxuan Shen; Veikko Linko; Mauri A Kostiainen
Journal:  ACS Omega       Date:  2019-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.